Klaus‐Michael Debatin

51.0k citations

521 papers · 33.1k indexed · 9 hit papers · h-index 85

Impact in

Immunology top 0.1%
- Immune Cell Function and Interaction
- interferon and immune responses
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
Cancer Research top 0.1%
- NF-κB Signaling Pathways

Papers in

Immunology 145
- Immune Cell Function and Interaction 43
Cancer Research 73
- NF-κB Signaling Pathways 30

Co-authors: Simone Fulda Peter H. Krammer Ingrid Herr Claudia Friesen Jens Dhein Henning Walczak Irmela Jeremias Martin Wabitsch
Journals: Blood (60 papers)Oncogene (32 papers)International Journal of Cancer (19 papers)Cancer Research (13 papers)Leukemia (12 papers)
Partner nations: Germany United States France

In The Last Decade

Klaus‐Michael Debatin

510 papers receiving 32.5k citations

Hit Papers

9 papers align trajectories log scale

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy 2006 · 1.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Oncogene
2002 Nature Medicine
2001 Blood
1996 Nature Medicine
1995 Science
1995 Nature
1995 Nature
1993 PubMed
1989 Science

Peers

Countries citing papers authored by Klaus‐Michael Debatin

Since Specialization

Citations

This map shows the geographic impact of Klaus‐Michael Debatin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus‐Michael Debatin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus‐Michael Debatin more than expected).

Fields of papers citing papers by Klaus‐Michael Debatin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus‐Michael Debatin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus‐Michael Debatin. The network helps show where Klaus‐Michael Debatin may publish in the future.

Co-authors

The 25 scholars most cited alongside Klaus‐Michael Debatin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Klaus‐Michael Debatin Line = papers co-authored together Klaus‐Michael Debatin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax Leukemia ·Alexandra Niedermayer, Jana Stursberg, Anke K. Bergmann, Martin Zimmermann, Gunnar Cario, Monika Brüggemann, Rolf Köhler, Daniel Steinbach, Christian Reimann, Felix Seyfried, Lüder Hinrich Meyer, Klaus‐Michael Debatin	2025	0
2	The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours Molecular Oncology ·Matthias Schneider, Anna‐Laura Potthoff, Georg Karpel‐Massler, Patrick Schuss, Markus D. Siegelin, Klaus‐Michael Debatin, Hugues Duffau, Hartmut Vatter, Ulrich Herrlinger, Mike‐Andrew Westhoff	2024	6
3	Lipodystrophy as a Late Effect after Stem Cell Transplantation Journal of Clinical Medicine ·Daniel Tews, Ansgar Schulz, Christian Denzer, Julia von Schnurbein, Giovanni Ceccarini, Klaus‐Michael Debatin, Martin Wabitsch	2021	7
4	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis Clinical Cancer Research ·Carmen Dorneburg, Matthias Fischer, Thomas F.E. Barth, Wolfgang Mueller‐Klieser, Barbara Hero, Judith Gecht, Daniel R. Carter, Katleen De Preter, Benjamin Mayer, Lisa Christner, Frank Speleman, Glenn M. Marshall, Klaus‐Michael Debatin, Christian Beltinger	2018	54
5	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias Molecular Cancer Therapeutics ·Maria Vittoria Verga Falzacappa, Chiara Ronchini, Mario Faretta, Ilaria Iacobucci, Andrea Ghelli Luserna di Rorà, Giovanni Martinelli, Lüder Hinrich Meyer, Klaus‐Michael Debatin, Stefania Orecchioni, Francesco Bertolini, Pier Giuseppe Pelicci	2015	25
6	Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma Molecular Cancer Research ·Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Georg Karpel‐Massler, Claudia Jennewein, Matthias Schneider, Marc‐Eric Halatsch, Neil O. Carragher, Bernd Baumann, Alexander Krause, Thomas Simmet, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin	2013	58
7	Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells Molecular Cancer Therapeutics ·Georg Karpel‐Massler, Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Annika Dwucet, Richard E. Kast, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin, Marc‐Eric Halatsch	2013	48
8	NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation–Induced Apoptosis Molecular Cancer Therapeutics ·Rebecca Berger, Claudia Jennewein, Viola Marschall, Sabine Karl, Silvia Cristofanon, Liane Wagner, Sri HariKrishna Vellanki, Stephanie Hehlgans, Franz Rödel, Klaus‐Michael Debatin, Albert C. Ludolph, Simone Fulda	2011	67
9	Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway Clinical Cancer Research ·Ivonne Naumann, Roland Kappler, Dietrich von Schweinitz, Klaus‐Michael Debatin, Simone Fulda	2011	51
10	Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma Clinical Cancer Research ·Daniela Opel, Ivonne Naumann, Maxi Schneider, Daniela Bertele, Klaus‐Michael Debatin, Simone Fulda	2011	55
11	TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors Clinical Cancer Research ·Dominic Stadel, Andrea Mohr, Caroline Ref, Marion MacFarlane, Shaoxia Zhou, Robin Humphreys, Max G. Bachem, Gerry Cohen, Peter Möller, Ralf M. Zwacka, Klaus‐Michael Debatin, Simone Fulda	2010	61
12	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia Cancer Research ·Sandra Loeder, Thorsten Zenz, Andrea Schnaiter, Daniel Mertens, Dirk Winkler, Hartmut Döhner, Klaus‐Michael Debatin, Stephan Stilgenbauer, Simone Fulda	2009	45
13	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling The Journal of Experimental Medicine ·Gudrun Strauß, Jonathan A. Lindquist, Nathalie J. Arhel, Edward Felder, Sabine Karl, Tobias L. Haas, Simone Fulda, Henning Walczak, Frank Kirchhoff, Klaus‐Michael Debatin	2009	28
14	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma Cancer Research ·Meike Vogler, Henning Walczak, Dominic Stadel, Tobias L. Haas, Felicitas Genze, Marjana Jovanovic, Umesh Bhanot, Cornelia Hasel, Peter Möller, Jürgen E. Gschwend, Thomas Simmet, Klaus‐Michael Debatin, Simone Fulda	2009	121
15	Targeting XIAP Bypasses Bcl-2–Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo Cancer Research ·Meike Vogler, Henning Walczak, Dominic Stadel, Tobias L. Haas, Felicitas Genze, Marjana Jovanovic, Jürgen E. Gschwend, Thomas Simmet, Klaus‐Michael Debatin, Simone Fulda	2008	135
16	Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor– and Drug-Induced Apoptosis Cancer Research ·Daniela Opel, Mike‐Andrew Westhoff, Ariane Bender, Veit Braun, Klaus‐Michael Debatin, Simone Fulda	2008	123
17	Activation of Akt Predicts Poor Outcome in Neuroblastoma Cancer Research ·Daniela Opel, Christopher Poremba, Thorsten Simon, Klaus‐Michael Debatin, Simone Fulda	2007	198
18	Loss of Caspase-8 Expression Does Not Correlate with MYCN Amplification, Aggressive Disease, or Prognosis in Neuroblastoma Cancer Research ·Simone Fulda, Christopher Poremba, Bernd Berwanger, Sabine Häcker, Martin Eilers, Holger Christiansen, Barbara Hero, Klaus‐Michael Debatin	2006	33
19	Sensitization for γ-Irradiation–Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase Cancer Research ·Stavros Giagkousiklidis, Meike Vogler, Mike‐Andrew Westhoff, Hubert Kasperczyk, Klaus‐Michael Debatin, Simone Fulda	2005	61
20	Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Mediated Proliferation of Tumor Cells with Receptor-Proximal Apoptosis Defects Cancer Research ·Eva Baader, Agnieszka Toloczko, Uta Fuchs, Irene Schmid, Christian Beltinger, Harald Ehrhardt, Klaus‐Michael Debatin, Irmela Jeremias	2005	74

About Klaus‐Michael Debatin

Klaus‐Michael Debatin is a scholar working on Immunology, Cancer Research, Molecular Biology, Hematology and Oncology, having authored 521 papers that have together received 33.1k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (177 papers), RNA Interference and Gene Delivery (53 papers), Acute Lymphoblastic Leukemia research (46 papers), Neuroblastoma Research and Treatments (44 papers), Immune Cell Function and Interaction (43 papers), Cancer therapeutics and mechanisms (32 papers), Cancer-related Molecular Pathways (31 papers) and NF-κB Signaling Pathways (30 papers). The work is most often cited by research in Immunology (9.1k citations), Cancer Research (5.1k citations), Molecular Biology (20.6k citations), Virology (1.3k citations) and Oncology (6.5k citations). Klaus‐Michael Debatin has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Simone Fulda, Peter H. Krammer, Ingrid Herr, Claudia Friesen, Jens Dhein, Henning Walczak, Irmela Jeremias, Martin Wabitsch, Éric Meyer and Caroline Bäumler. Their work appears in journals such as Blood, Oncogene, International Journal of Cancer, Cancer Research and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact